

Welcome to STN International! Enter x:x

LOGINID:sssptal600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Jun 03 New e-mail delivery for search results now available
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24 BEILSTEIN adds new search fields
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17 TOXCENTER enhanced with additional content
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 20 Feb 13 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27 Mar 20 EVENTLINE will be removed from STN
NEWS 28 Mar 24 PATDPAFULL now available on STN
NEWS 29 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 30 Apr 11 Display formats in DGENE enhanced
NEWS 31 Apr 14 MEDLINE Reload
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 33 Apr 21 Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 35 Apr 28 RDISCLOSURE now available on STN
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 38 May 15 Supporter information for ENCOMPAT and ENCOMPLIT updated
NEWS 39 May 16 CHEMREACT will be removed from STN
NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:40:09 ON 23 MAY 2003

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 16:41:16 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9
DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10069824.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 16:41:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      67 TO ITERATE

100.0% PROCESSED      67 ITERATIONS      0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   849 TO    1831
PROJECTED ANSWERS:      0 TO      0

L2      0 SEA SSS SAM L1


=> s l1 full
FULL SEARCH INITIATED 16:41:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    1467 TO ITERATE

100.0% PROCESSED    1467 ITERATIONS      2 ANSWERS
SEARCH TIME: 00.00.01

L3      2 SEA SSS FUL L1

=> d scan
```


L3 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 19 Indole-3-glyoxylamide, 4-(benzyloxy)-3-methoxy-N,N-dimethyl- (7CI, 8CI)
 MF C20 H20 N2 O4



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (3):1

L3 2 ANSWERS REGISTRY COPYRIGHT 2003 ACS
 19 Indole-3-glyoxylamide, 4,5,6-trimethoxy-N,N-dimethyl- (7CI)
 MF C19 H18 N2 O5



***PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

ALL ANSWERS HAVE BEEN SCANNED

=> fill caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.57

FILE 'CAPLUS' ENTERED AT 16:41:56 ON 23 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2003 VOL 138 ISS 22

FILE LAST UPDATED: 22 May 2003 (20030522/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4

2 L3

=> d ibib abs hitstr 1-2



=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.49	158.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.30	-1.30

FILE 'REGISTRY' ENTERED AT 16:42:20 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9
DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 10069824.str

L5 STRUCTURE UPLOADED

=> d
L5 HAS NO ANSWERS
L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 15

SAMPLE SEARCH INITIATED 16:42:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 219 TO ITERATE

100.0% PROCESSED 219 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3493 TO 5267
PROJECTED ANSWERS: 1114 TO 2206

L6 50 SEA SSS SAM L5

=> s 15 full

FULL SEARCH INITIATED 16:42:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4540 TO ITERATE

100.0% PROCESSED 4540 ITERATIONS 1927 ANSWERS
SEARCH TIME: 00.00.01

L7 1927 SEA SSS FUL L5

=>


Uploading 10069824.str

L8 STRUCTURE UPLOADED

=> d

L8 HAS NO ANSWERS

L8 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 18 subset=17 full

FULL SUBSET SEARCH INITIATED 16:44:11 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1927 TO ITERATE

100.0% PROCESSED 1927 ITERATIONS 570 ANSWERS

SEARCH TIME: 00.00.01

L9 570 SEA SUB=L7 SSS FUL L8

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	183.85	341.91
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.30

FILE 'CAPLUS' ENTERED AT 16:44:16 ON 23 MAY 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2003 VOL 138 ISS 22
 FILE LAST UPDATED: 22 May 2003 (20030522/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19
 L10 221 L9

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	342.33
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.30

FILE 'REGISTRY' ENTERED AT 16:44:42 ON 23 MAY 2003
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10069824.str

L11 STRUCTURE UPLOADED

=> d

L11 HAS NO ANSWERS

L11 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l11 subset=l9 full

FULL SUBSET SEARCH INITIATED 16:45:00 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 570 TO ITERATE

100.0% PROCESSED 570 ITERATIONS

484 ANSWERS

SEARCH TIME: 00.00.01

L12 484 SEA SUB=L9 SSS FUL L11

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

35.30 377.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

0.00 -1.30

FILE 'CAPLUS' ENTERED AT 16:45:03 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 22 May 2003 (20030522/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l12
L13      193 L12


=> s l13 and spla
          36 SPLA
L14      5 L13 AND SPLA

=> s l13 and spla2
          531 SPLA2
L15      37 L13 AND SPLA2


=> d ibib abs hitstr 1-37
```


L15 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

RM 443911-30-6 CAPLUS
 CN Acetic acid, [[3-[(aminooxyacetyl)-1-(cyclohexylmethyl)-2-methyl-1H-benz[*g*]indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 443911-31-7 CAPLUS
 CN Acetic acid, [(3-[aminooxoacetyl]-1-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2-methyl-1H-benz[9]indol-4-yl)oxy]-, methyl ester (9CI) (CA
 INDEX NAME)



RN 443911-32-8 CAPLUS
 CN Acetic acid, [(3-(aminooxocostyl)-1-[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]-2-methyl-1H-benz[*g*]indol-4-yl)oxy]-(9CI) (CA INDEX NAME)

E15 ANSWER 3 OF 37 CARLIS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002-467526 CAP US
 DOCUMENT NUMBER: 13747112
 TITLE: Novel β -LAP inhibitors
 INVENTOR(S): Wright, Douglas Wade; Kinnick, Michael Deane; Lin, Hu-Shen; Marini, John Michael, Jr.; Richetti, Michael Enrico; Sali, Daniel Jon; Sawyer, Jason Scott; Smith, Edward C. R.
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 174 pp.
 DOCUMENT TYPE: CODEM: P13X02
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 1

[illegible]


ABSTRACT SOURCE(S): MUAUPAT 137:47312

AA A novel class of cycloalkyl fused indole compds. is disclosed together with such compds. for inhibiting *APL*A2 mediated release of fatty acids for treatment of insulin resistance diseases such as metabolic shock. A series of cycloalkyl fused indole compounds were prepared by several steps and methods and were tested as inhibitors of *APL*A2. E.g., 2-[(4-(2-benzene-sulfonyl-phenyl)-2-oxoethoxy)-1-benzyl]-2-methyl-1,6,7,8-tetrahydro-1-aza-as-indacen-3-yl]-2-methoxyacetate, 2-[[3-(2-amino-2-methyl-1-phenyl)-2-oxoethyl]-2-oxoethyl]-2-methyl-1,6,7,8-tetrahydrocyclopent[3,1-indol-4-yl]oxyacetic acid, and 2-[[1-(2-amino-1,2-dioxomethyl)-1-benzyl]-2-methyl-6,7,8-tetrahydro-1H-benz[3,1-indol-6-yl]oxy]acetic acid exhibited IC50 values of 0.007, 0.009 and 0.010 μ M, M.


IT 438622-56-4P 438622-58-6P 438622-59-7P
438622-61-1P 438622-63-3P 438622-65-5P
438622-67-7P 438622-69-9P 438622-71-3P
438622-73-5P 438622-75-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPM (Synthetic preparation); BIOI (Biological study); PREP (Preparation); RACT (Reactant or reagent)

RN 436623-56-4 CAPLUS
 CN Acetic acid, [(3-(α -methoxyacetyl)-2-ethyl-1,6,7,8-tetrahydro-1-phenylmethyl)cyclopent[*g*]indol-4-yl]oxy]-, methyl ester (5CI) (CA INOEX NAME)


L15 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



E15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 438623-58-6 CAPLUS
 CN Acetic acid, [[3-(aminocyclohexyl)-1,6,7,8-tetrahydro-2-methyl-1-(phenylmethyl)cyclopent[5]indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX
 N04047)



RN 438623-59-7 CAPLUS
CN Acetic acid, [[3-[aminooxoacetyl]-1,6,7,8-tetrahydro-2-methyl-1-(phenylmethyl)cyclopent[9]indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




FW 438623-61-1 CAPLUS
CN Acetic acid, [[3-(4aminooxoacetyl)-1-[(3-fluorophenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl]oxy]-, methyl ester (9CI) (CAPLUS NAME)




L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RX 436623-63-3 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(4-fluorophenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

RX 436623-65-5 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

RX 436623-67-7 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-4,7,8-tetrahydro-1-(phenylmethyl)-3H-benz[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RX 436623-75-7 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(5-bromo-2-thienylphenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

RX 436623-75-7 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(5-bromo-2-thienylphenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

RX 436623-75-7 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(5-bromo-2-thienylphenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)

RX 436623-60-0 CAPLUS


CN Cycloimino[*g*]indole-3-acetamide, 1,6,7,8-tetrahydro-2-methyl-, alpha-, omega-

L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RX 436623-66-6 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-6,7,8-tetrahydro-2-methyl-1-(phenylmethyl)-3H-benz[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


RX 436623-71-3 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-(2-(4-oxocyclohexyl)methyl)-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


RX 436623-73-5 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(4-oxocyclohexyl)methyl)-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


RX 436623-62-2 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-(4-fluorophenyl)methyl)-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


RX 436623-64-4 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-(4-fluorophenyl)methyl)-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


RX 436623-66-6 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[*g*]indol-4-yl)oxy]-, methyl ester (9CI) (CA INDEX NAME)


L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RU 438623-66-8 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-ethyl-6,7,8-tetrahydro-1-phenylmethyl)-1H-benz[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)




RU 438623-70-2 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-ethyl-6,7,8-tetrahydro-2-methyl-1-phenylmethyl)-1H-benz[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)




RU 438623-72-4 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-[(2-bromophenyl)methyl]-1,6,7,8-tetrahydro-2-methylcyclopent[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)

L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


L15 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RU 438623-74-6 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-1,6,7,8-tetrahydro-2-methylcyclopent[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)



RU 438623-76-8 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-[(2-(5-bromo-2-thienylphenyl)methyl)-1,6,7,8-tetrahydro-2-methylcyclopent[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)




L15 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001-087524 CAPLUS
 137:47110
 TITLE: Novel μ AS inhibitors
 INVENTOR(S): Weisbro, Douglas Veder, Kinnick, Michael Deani Lin, Mc-Shen, Martin, John Michael, Jr., Rickett, Michael
 SOURCE: Sanofi-Schering-Plough Research Institute, Kenilworth, NJ, USA
 PATENT ASSIGNOR(S): Schering-Plough Research Institute, Kenilworth, NJ, USA
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030028	A2	20020627	WO 2001-043184	20011206
WO 2002030028	A3	20020919		
US 6,240,000	A1	20010627		
US 6,240,000	A2	20010627		
US 6,240,000	A3	20010627		
US 6,240,000	A4	20010627		
US 6,240,000	A5	20010627		
US 6,240,000	A6	20010627		
US 6,240,000	A7	20010627		
US 6,240,000	A8	20010627		
US 6,240,000	A9	20010627		
US 6,240,000	A10	20010627		
US 6,240,000	A11	20010627		
US 6,240,000	A12	20010627		
US 6,240,000	A13	20010627		
US 6,240,000	A14	20010627		
US 6,240,000	A15	20010627		
US 6,240,000	A16	20010627		
US 6,240,000	A17	20010627		
US 6,240,000	A18	20010627		
US 6,240,000	A19	20010627		
US 6,240,000	A20	20010627		
US 6,240,000	A21	20010627		
US 6,240,000	A22	20010627		
US 6,240,000	A23	20010627		
US 6,240,000	A24	20010627		
US 6,240,000	A25	20010627		
US 6,240,000	A26	20010627		
US 6,240,000	A27	20010627		
US 6,240,000	A28	20010627		
US 6,240,000	A29	20010627		
US 6,240,000	A30	20010627		
US 6,240,000	A31	20010627		
US 6,240,000	A32	20010627		
US 6,240,000	A33	20010627		
US 6,240,000	A34	20010627		
US 6,240,000	A35	20010627		
US 6,240,000	A36	20010627		
US 6,240,000	A37	20010627		
US 6,240,000	A38	20010627		
US 6,240,000	A39	20010627		
US 6,240,000	A40	20010627		
US 6,240,000	A41	20010627		
US 6,240,000	A42	20010627		
US 6,240,000	A43	20010627		
US 6,240,000	A44	20010627		
US 6,240,000	A45	20010627		
US 6,240,000	A46	20010627		
US 6,240,000	A47	20010627		
US 6,240,000	A48	20010627		
US 6,240,000	A49	20010627		
US 6,240,000	A50	20010627		
US 6,240,000	A51	20010627		
US 6,240,000	A52	20010627		
US 6,240,000	A53	20010627		
US 6,240,000	A54	20010627		
US 6,240,000	A55	20010627		
US 6,240,000	A56	20010627		
US 6,240,000	A57	20010627		
US 6,240,000	A58	20010627		
US 6,240,000	A59	20010627		
US 6,240,000	A60	20010627		
US 6,240,000	A61	20010627		
US 6,240,000	A62	20010627		
US 6,240,000	A63	20010627		
US 6,240,000	A64	20010627		
US 6,240,000	A65	20010627		
US 6,240,000	A66	20010627		
US 6,240,000	A67	20010627		
US 6,240,000	A68	20010627		
US 6,240,000	A69	20010627		
US 6,240,000	A70	20010627		
US 6,240,000	A71	20010627		
US 6,240,000	A72	20010627		
US 6,240,000	A73	20010627		
US 6,240,000	A74	20010627		
US 6,240,000	A75	20010627		
US 6,240,000	A76	20010627		
US 6,240,000	A77	20010627		
US 6,240,000	A78	20010627		
US 6,240,000	A79	20010627		
US 6,240,000	A80	20010627		
US 6,240,000	A81	20010627		
US 6,240,000	A82	20010627		
US 6,240,000	A83	20010627		
US 6,240,000	A84	20010627		
US 6,240,000	A85	20010627		
US 6,240,000	A86	20010627		
US 6,240,000	A87	20010627		
US 6,240,000	A88	20010627		
US 6,240,000	A89	20010627		
US 6,240,000	A90	20010627		
US 6,240,000	A91	20010627		
US 6,240,000	A92	20010627		
US 6,240,000	A93	20010627		
US 6,240,000	A94	20010627		
US 6,240,000	A95	20010627		
US 6,240,000	A96	20010627		
US 6,240,000	A97	20010627		
US 6,240,000	A98	20010627		
US 6,240,000	A99	20010627		
US 6,240,000	A100	20010627		

OTHER SOURCE(S): HANPAT 137:47110




AB A novel class of benz[glindole] compounds, is disclosed together with such compounds for inhibiting μ AS mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, benz[glindole] 1, propyl, is novel class of μ AS inhibitors, exhibiting an inhibition value IC50 of 1.06 μ M against μ AS.


IT 438623-87-4 CAPLUS
 Al: PAC (Pharmacological activity); SPN (Synthetic preparation); B101 (Biological study); PEP (Preparation)
 [Group of benz[glindole] as μ AS inhibitors]

RU 438623-87-4 CAPLUS
 Acetic acid, [(3-(aminomonoacetyl)-1-ethyl-1-phenylmethyl)-1H-benz[glindol-4-yl]oxy]- (FC1) (CA INDEX NAME)


L15 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
4-yl)oxy)-, ethyl ester (EC) (CA INDEX NAME)



NX 435587-44-5 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-benz[f]indol-4-yl]oxy]-, phenylmethyl ester (EC) (CA INDEX NAME)




NX 435587-49-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)




IT 435587-51-0P 435587-51-0P 435587-52-1P
435587-53-2P 435587-54-3P 435587-55-4P
435587-56-5P 435587-57-6P 435587-58-7P
NLI SPN (Synthetic preparation) PREP (Preparation)
NLI SPN (Synthetic preparation) PREP (Preparation)

NX 435587-50-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



NX 435587-54-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-fluorophenyl)methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)




NX 435587-55-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-benz[f]indol-4-yl]oxy]-, methyl ester (EC) (CA INDEX NAME)




NX 435587-56-5 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



NX 435587-51-0 CAPLUS
CN 1H-benz[f]indol-3-ecarboxamide, 2-methyl-, alpha-methoxy-4-[(2-oxo-2-[(phenylmethyl)amino]ethoxy)-1-(phenylmethyl)- (EC) (CA INDEX NAME)




NX 435587-52-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-fluorophenyl)methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]-, methyl ester (EC) (CA INDEX NAME)




NX 435587-53-2 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-fluorophenyl)methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




NX 435587-57-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-yl]methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)




NX 435587-58-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2-bromophenyl)methyl]-2-methyl-1H-benz[f]indol-4-yl]oxy]- (EC) (CA INDEX NAME)




L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-65-9 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-((2,6-dichlorophenyl)methyl)-2-methyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




RN 172732-66-0 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-((4-fluorophenyl)methyl)-2-methyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




RN 172732-67-1 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-((1-naphthalenyl)methyl)-2-methyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)


L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-71-7 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)



RN 172732-72-8 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)



RN 172732-73-9 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




RN 172732-74-0 CAPLUS
 CN Pyranic acid, 4-([3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy)- (9CI) (CA INDEX NAME)


L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-68-3 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-([3-chlorophenyl]methyl)-2-ethyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




RN 172732-70-6 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)


L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-68-3 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy-, methyl ester (9CI) (CA INDEX NAME)




RN 172732-42-5 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy-, monosodium salt (9CI) (CA INDEX NAME)




• Na

RN 246730-08-3 CAPLUS
 CN Acetic acid, [13-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)

L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 249730-11-8 CAPLUS
 CN Acetic acid, [[3-(acetyloxycarbonyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, 2-[(4-morpholinyl)ethyl] ester (9CI) (CA INDEX NAME)




RN 391936-25-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-

```

LIS ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:10441 CAPLUS
DOCUMENT NUMBER: 196:60735
TITLE: Preparation of heterocyclic compounds as X-type
       $\mu$ -I2 inhibitors
INVENTOR(S): Ojawa, Tomoyuki; Sano, Kaoru; Hanasaki, Kohji; Ikeda,
      Masahito; Ogo, Takashi
PATENT ASSIGNOR(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 87 pp.
      CODING: #10002
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```


[illegible]

AB The title compds., e.g. I [R20 is OCH₂COOH or the like; R21 is COCOCH₂ or the like; R22 is C4-6 alkyl; R23 is CH₂R18 (wherein R18 is aryl or the like); and R24 is hydrogen or Cl-6 alkyl], are prepd. The title compd. II in vitro showed IC₅₀ of 0.004 μ M against X-type sPLA₂.

Formulations are given.

17 383880-18-3P 383880-20-8P 383880-21-7P
383880-22-8P 383880-23-9P 383880-24-0P


L15 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
ylloxy]-, monosodium salt [SCI] (CA INDEX NAME)




L15 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

363880-30-8P 363880-31-8P 363880-32-0P
363880-33-1P 363880-34-2P 363880-35-3P
363880-36-4P 363880-37-5P 363880-38-8P
363880-44-4P 363880-47-7P
EL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BLO (Biological study); PREP (Preparation); USDS (Uses)


(prepn. of heterocyclic compds. as K-type ϵ PLA2 inhibitors)
 RN 303860-12-3 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-(2-methylpropyl)-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 383460-20-6 CAPLUS
 CN Acetic acid, [(3-(aminooxyacetyl)-1-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-1H-indol-4-yl)oxy]-(9C) (CA INDEX NAME)




RM 363660-21-7 CAPLUS
 CN Acetic acid, [3-(aminooxyacetyl)-1-(cyclohexylethyl)-2-(2-methylpropyl)-1H-indol-4-yl]oxy)- (9CI) (CA INDEX NAME)




FN 383460-22-4 CAPLUS
 CN Acetic acid, [[3-(amino-oxoacetyl)-6-methyl-2-(2-methylpropyl)-1-(phenylmethyl)-1H-indol-4-yl]oxy]-(9CI) (CA INDEX NAME)


L15 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 383860-23-9 CAPLUS
CN Acetic acid, [(3-(1-aminomethyl)-2-(2-methylpropyl)-1-phenyl-1H-indol-4-yl)amino]- (PCI) (CA INDEX NAME)




RN 383860-24-0 CAPLUS
CN 18-Indole-3-acetamide, 6-methyl-2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-30-8 CAPLUS
CN 18-Indole-3-acetamide, 2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino]-1-phenylethyl-1- (PCI) (CA INDEX NAME)


L15 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 383860-34-2 CAPLUS
CN 18-Indole-3-acetamide, 4-[(2-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-36-3 CAPLUS
CN 18-Indole-3-acetamide, 2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-36-4 CAPLUS
CN 18-Indole-3-acetamide, 4-[(2-[(1-methyl-1H-indol-4-yl)sulfonyl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)


L15 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 383860-31-9 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-32-0 CAPLUS
CN 18-Indole-3-acetamide, 2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-33-1 CAPLUS
CN 18-Indole-3-acetamide, 6-methyl-2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




L15 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 383860-37-5 CAPLUS
CN 18-Indole-3-acetamide, 4-[(2-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)




RN 383860-38-6 CAPLUS
CN 18-Indole-3-acetamide, 2-[(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)



RN 383860-44-4 CAPLUS
CN 18-Indole-3-acetamide, 4-[(2-[(4-fluorophenyl)methyl]-2-(2-methylpropyl)-1-phenyl-1H-indol-4-yl]amino)-2-oxoethoxy]-1-phenylethyl-1- (PCI) (CA INDEX NAME)


116 ANSWER 6 OF 37 CAPLES COPYRIGHT 2003 ACS (Continued)



FN 383860-47-7 CAPLUS
 CN 1H-Indole-3-acetamide, 2-(2-methylpropyl)-.alpha.-cnc-1-(phenylmethyl)-4-(1H-tetrazol-5-ylmethoxy)- (9CI) (CA INDEX NAME)



1Y 383860-68-2P 383860-74-8P
 AL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of heterocyclic compds. as X-type #1A2 inhibitors)
 7N 383860-68-2 CAPUS
 CN Acetic acid, [13-(aminooxocacetyl)-2-(2-methylpropyl)-1-(phenylmethyl)-1H-
 indol-6-yl]oxyl-, methyl ester (9CI) [CA INDEX NAME]




RM	383860-74-0	CAPLUS
CN	1H-Indole-3-acetamide, 4-(cyanomethoxy)-2-(2-methylpropyl)-, alpha.-oxo-1-(phenylmethyl)- (5CI)	(CA INDEX NAME)

[illegible]

```


OTHER SOURCE(S): MARPAT 136:64151
AD  It is found out that type X  $\beta$ -glucosidase inhibitors are useful in
IT  preventing or treating Alzheimer's disease.
172332-64-2 172332-70-6 172332-80-5
Rf: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(secondary  $\beta$ -glucosidase inhibitors as remedies for Alzheimer's disease)
XN  172332-64-2 CATION
CN  Acetic acid, (1 $\beta$ -(adonocinnamoyloxy)-2-ethyl-1-(phenylmethyl)-1H-indol-4-
yl)oxy- (9CI) (CIN INDEX NAME)

```




RN 172732-70-6 CAPLUS
 CN Acetic acid, [1-(aminooxyacetyl)-1-([1,1'-biphenyl]-2-yl)ethyl]-2-ethyl-1H-indol-4-yl]oxy)-(9CI) (CA INDEX NAME)

115 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




HN 238262-50-9 CAPLUS
 CN 1H-Indole-3-acetamide, 2-ethyl-.alpha.-oxo-4-[2-oxo-2-
 [(phenylsulfonyl)amino]ethoxy]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

249730-11-8 CAPLUS
Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



IT 172733-06-3
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of 1H-indole-3-glyoxylamide compds. as aPLA2
 inhibitors)
 RN 172733-08-3 CAPLUS
 CN Acetic acid, [[3-(aminooxocarbonyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (SCI) (CA INDEX NAME)



IT	172732-80-8P Nls: RCT (Resistant); SYN (Synthetic preparation); PREP (Preparation); NACT (Resistant or reagent) (prepn. of 1H-indole-3-glyoxylamide compds. as apLAs inhibitors)
RN	172732-80-8 CAPUS
CM	Acetic acid, [(3-(aminooxooxocetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]-, methyl ester (SC) (CA INDEX NAME)

L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Acetic acid, [[3-(aminooxocetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-


ACCESSION NUMBER:	2001:67601 CAPUS
DOCUMENT NUMBER:	135:236446
TITLE:	Compositions containing potential secretory phospholipase A2 (sPLA2) inhibitors for the treatment of pain
INVENTOR(S):	Macias, William Louis
PATENT ASSIGNOR(S):	ICI Lilly and Company, USA
SOURCE:	EC2 Int. Appl., 156 pp. CODE: P1XXB2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

[illegible]



AB A method is disclosed for the treatment of pain by administering to an animal in need thereof a therapeutically effective amt. of a $\text{AFI}A2$ inhibitor, e.g. a 1H-indole-3-glyoxylamide or $\text{AFI}A2$ inhibitor in combination with propoxyphene. Prep'n. of $\{[3-(2\text{-Amino-1,2-dioxoethyl})-2\text{-ethyl-1-phenylethyl}]\text{-1H-indol-4-yl}\}$ oxyacetic acid is described.

172733-06-3
 R1: BAC (Biological activity or effector, except adverse); BSW (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
 (secretory phospholipase A2 inhibitors for treatment of pain)

172733-08-3 CAPLUS
 Acetic acid, [(3-(aminooxocacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl)oxy]-, methyl ester (SCI) (CA INDEX NAME)




17 172732-66-2P
NA: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
[secretory phospholipase A2 inhibitors for treatment of pain]
17 172732-66-2 CAPUS




17 172732-60-6 172732-60-40, derivs. 172732-61-5
172732-61-80, derivs. 172732-62-6 172732-62-60
, derivs. 172732-63-7 172732-63-70, derivs.
172732-64-8 172732-64-80, derivs. 172732-65-9
172732-66-90, derivs. 172732-66-0 172732-66-30
, derivs. 172732-67-1 172732-67-10, derivs.
172732-68-20, derivs. 172732-68-3 172732-68-60
, derivs. 172732-70-6 172732-70-40, derivs.
172732-71-7 172732-71-70, derivs. 172732-72-6
172732-72-80, derivs. 172732-73-9 172732-73-80
172732-74-0 172732-74-00, derivs.
172732-75-0

AL: SAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BLO (Biological study); USES (Uses)
(secretory phospholipase A2 inhibitors for treatment of pain)
RW 172732-60-4 CAPLUS
CN Acetic acid, [1-[(3-aminomonoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-




RN 172732-60-4 CAPLUS
 CN Acetic acid, [[3-(aminooxyacetyl)-2-methyl-1-(phenyl)methyl]-1H-indol-4-yl]oxy]- (5C1) (CA INDEX NAME)


L16 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-61-5 CAPLUS
CN Propanoic acid, 2-[[3-(aminooxoacetyl)-2-methyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-61-5 CAPLUS
CN Propanoic acid, 2-[[3-(aminooxoacetyl)-2-methyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-62-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-64-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)



RN 172732-64-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-65-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[2,6-dichlorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-65-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[2,6-dichlorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-62-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-63-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-63-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)


L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-66-0 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[4-fluorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)



RN 172732-66-0 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[4-fluorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)



RN 172732-67-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenylethyl)-1H-indol-4-yl]oxy]- (EC) (CA INDEX NAME)




RN 172732-67-1 CAPLUS


L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-68-2 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-71-7 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-72-8 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-72-8 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-70-6 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-70-6 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-71-7 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 172732-73-9 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-73-9 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-74-0 CAPLUS
 CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-74-0 CAPLUS
 CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




CC(=O)C(=O)Nc1c2ccccc2c(c1)C(=O)OCC(=O)O

L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


NM 172732-63-7 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-64-8 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



NM 172732-64-8 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



NM 172732-65-9 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

NM 172732-67-1 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-67-1 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



NM 172732-68-2 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



NM 172732-68-2 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




NM 172732-65-9 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-66-0 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-66-0 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




NM 172732-69-3 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-69-3 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



NM 172732-70-6 CAPLUS


CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




NM 172732-70-6 CAPLUS

CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
18-indol-4-yl]oxy)- (PCT) (CA INDEX NAME)



HN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl]-2-ylmethyl)-2-propyl-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)




HN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl]-2-ylmethyl)-2-propyl-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)




HN 172732-72-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)

L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


HN 172732-74-0 CAPLUS
CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-18-indol-5-yl]oxy]- (PCT) (CA INDEX NAME)



HN 172732-74-0 CAPLUS
CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-18-indol-5-yl]oxy]- (PCT) (CA INDEX NAME)




HN 172732-08-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-18-indol-4-yl]oxy]-, methyl ester (PCT) (CA INDEX NAME)




HN 172732-42-5 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-18-indol-4-yl]oxy]-, monomodium salt (PCT) (CA INDEX NAME)


L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




HN 172732-72-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)




HN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)



HN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl]-2-ylmethyl)-2-cyclopropyl-18-indol-4-yl]oxy]- (PCT) (CA INDEX NAME)




L15 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



• Na


L15 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-66-0 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-66-0 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-67-1 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-69-3 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-70-6 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-70-6 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-67-1 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-68-2 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-68-2 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-71-7 CAPLUS

CN Acetic acid, [[3-(aminomonoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-71-7 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-72-6 CAPLUS


CN Acetic acid, [[3-(aminomonoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
ACCORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




L15 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 331440-95-0 CAPLUS

CN 18-Indole-3-acetamide, 4-[[2-[(1,1-dimethylamino)amino]-2-oxoethyl]-2-ethyl- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)

RN 331440-97-2 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl-4-[[2-[(2-methylpropoxy)amino]-2-oxoethyl]- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)


RN 331440-99-4 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl- α - α -4-[[2-oxo-2-[(phenylethoxy)amino]ethyl]-3-(phenylethyl)]- (SCI) (CA INDEX NAME)


RN 331441-01-3 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl-4-[[2-[(methylphenylmethoxy)amino]-2-oxoethyl]- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)

L15 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 331441-16-7 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl-4-[[2-[(hydroxy(phenylmethyl)amino)-2-oxoethyl]- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)


RN 331441-20-4 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl-4-[[2-[(hydroxy(1-methylethyl)amino)-2-oxoethyl]- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)

CN 1

CFN 331441-19-1


CMF C17 H23 N3 O5




CN 2

CFN 108-88-3


L15 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 331441-03-3 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl- α - α -4-[[2-oxo-2-[(phenylmethyl)amino]ethyl]-3-(phenylethyl)]- (SCI) (CA INDEX NAME)

RN 331441-05-5 CAPLUS

CN 18-Indole-3-acetamide, 2-ethyl-4-[[2-[(methylphenoxy)amino]-2-oxoethyl]- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)


RN 331441-07-7 CAPLUS

CN 18-Indole-3-acetamide, 4-[[2-(cyclohexylhydroxyamino)-2-oxoethyl]-2-ethyl- α - α -1-(phenylethyl)]- (SCI) (CA INDEX NAME)

L15 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




L15 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 321153-36-0 CAPLUS

CN L-tryptophan, N-[[[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)


Absolute stereochemistry.



RN 321153-38-2 CAPLUS

CN L-tryptophan, N-[[[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, dimethyl ester (SCI) (CA INDEX NAME)

Absolute stereochemistry.




RN 321153-40-6 CAPLUS

CN L-tryptophan, N-[[[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)

L15 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

yloxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FOWAT

L15 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


4-yl]oxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321153-42-8 CAPLUS


CN Propanedioic acid, [[[(3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]amino]-, dimethyl ester (SCI) (CA INDEX NAME)



RN 321153-44-0 CAPLUS

CN L-tryptophan, N-[[[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)

Absolute stereochemistry.



RN 321153-46-2 CAPLUS

CN L-tryptophan, N-[[[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetyl]-, methyl ester (SCI) (CA INDEX NAME)

L15 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2003 ACS

2000-109082 CAPLUS

133:321895

ACCESSION NUMBER:

DOCUMENT NUMBER:

TITLE:

INVENTOR(S):

PATENT APPLICATION(S):

SOURCE:

LANGUAGE:

DOCUMENT TYPE:

FAMILY AC. NOM. COUNT:

PATENT INFORMATION:

PUBLICATION NO. DATE

US 4440327 A 20001031 US 1999-101663 19990512

WO 2000-069114 A1 20001123 WO 2000-069114 20000509

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

US 4440327 A 20001031 US 1999-101663 19990512

A1 Title compound: $[X = CO, CH_2, X = X(CH_2)_n, (X = O, NH, S, bond, n = 1-3), CH_2CH_2, C, \text{lipbond}, C, \text{alkyl linker with chain length of } 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 8$


L15 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

see also reported.

IT 278794-38-6P 278794-38-6P
 RI: BAC (Biological activity) or effector, except adverse; BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BUD (Biological study); PABZ (Preparation); USES (Uses)
 (prepn. of substituted pyrrolindolonylacetate as aPLAS inhibitors)

RI 278794-38-6 CAPLUS


CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]- (PCI) (CA INDEX NAME)



RI 278794-37-9 CAPLUS

CH Acetic acid, [(13S)-9-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]- (PCI) (CA INDEX NAME)

Absolute stereochemistry.




RI 278794-38-0 CAPLUS

CH Acetic acid, [(13S)-9-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]- (PCI) (CA INDEX NAME)

Absolute stereochemistry.

L15 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 278794-38-7P

RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of substituted pyrrolindolonylacetate as aPLAS inhibitors)

RI 278794-38-7 CAPLUS

CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, methyl ester (PCI) (CA INDEX NAME)




IT 278794-38-1P 278794-40-6P 278794-41-5P

278794-42-6P 278794-43-7P 278794-44-8P
 RI: SPN (Synthetic preparation); THU (Therapeutic use); BUD (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of substituted pyrrolindolonylacetate as aPLAS inhibitors)

RI 278794-39-1 CAPLUS


CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, ethyl ester (PCI) (CA INDEX NAME)

L15 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RI 278794-40-4 CAPLUS

CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, propyl ester (PCI) (CA INDEX NAME)




RI 278794-41-5 CAPLUS

CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, 1-methyl-2-propyl ester (PCI) (CA INDEX NAME)



RI 278794-42-6 CAPLUS

CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, butyl ester (PCI) (CA INDEX NAME)



L15 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


278794-43-7 CAPLUS

CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, 2-(4-methylphenyl)-2-methoxy ester (PCI) (CA INDEX NAME)



RI 278794-44-8 CAPLUS


CH Acetic acid, [(9S)-[6-(aminooxycetyl)-2,3-dihydro-3-phenyl-1H-pyrrolo[1,2-a]indol-8-yl]oxy]-, 2-(4-methylphenyl)-2-methoxy ester (PCI) (CA INDEX NAME)




L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

172732-71-7 172732-71-70, produg deriva.
 172732-71-8 172732-71-80, produg deriva.
 172732-72-6 172732-72-60, produg deriva.
 172732-73-6 172732-73-60, produg deriva.
 172732-74-0 172732-74-00, produg deriva.
 172732-08-30, produg deriva. 172732-08-3
 172732-08-30, produg deriva. 249732-08-3
 249732-08-30, produg deriva.
 RU: RAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BSL (Biological study) / USES (activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

RN 172732-60-4 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-60-4 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-61-5 CAPLUS
 CN Propionic acid, 2-[[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-63-7 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-63-7 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-64-4 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-64-4 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-61-5 CAPLUS
 CN Propionic acid, 2-[[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-62-6 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-62-6 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-65-9 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-65-9 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-66-0 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-66-0 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-67-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-67-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-72-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-69-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-70-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-70-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 172732-72-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



RN 172732-74-0 CAPLUS
CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)




AS	The title compounds, [1: R1 = alkyl, (un)substituted CH2Ph, (CH2)2Ph, etc.; R2 = M, halo, alkyl, alk-1-enyl, R3 = CO2H, SO3H, PO(OH)2, etc.; R4 = M, alkyl, alkoxy, etc.], useful for inhibiting <i>APL2A</i> [no data], were prepared. E.g., a multi-step synthesis of 1 [R1 = CH2Ph; R2 = St; R4 = CO2H; R5 = H], was given.
IT	171238-68-2P 172733-00-3P RL: INV (Industrial manufacture); SYN (Synthetic preparation); PKER (Preparation) increases for prep. 4-substituted-1 <i>H</i> -indole-3-glycosides)
NO	172733-68-2 CAPUSU

RN 172732-67-1 CASUS
 CM Acetic acid, [[3-(aminooxyacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy] = (9CI) (CA INDEX NAME)


L15 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-68-2 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-1-[[3-(chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




RN 172732-70-6 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)


L15 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 211935-45-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-(aminomonoacetyl)-4-(carboxymethoxy)-2-ethyl-1-(phenylmethyl)- (SCI) (CA INDEX NAME)



RN 263910-31-2 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




RN 263910-32-3 CAPLUS
CN Succinic acid, 3-[[3-(aminomonoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




REFERENCE COUNT: 98 THERE ARE 98 CITED REFERENCES AVAILABLE FOR THIS


L15 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




RN 172732-72-8 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)




RN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminomonoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)


L15 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
yl]oxy)- (PCI) (CA INDEX NAME)

RN 172732-60-4 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-61-5 CAPLUS
CN Propanoic acid, 2-[(3-(aminooacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-61-5 CAPLUS
CN Propanoic acid, 2-[(3-(aminooacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)


L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172732-63-7 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)



RN 172732-64-8 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-66-8 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-65-9 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)


L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-62-6 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-62-6 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-63-7 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(1,1'-biphenyl)-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)


L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-65-9 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-66-8 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)




RN 172732-67-1 CAPLUS
CN Acetic acid, [(3-(aminooacetyl)-2-methyl-1-(1-naphthalenylmethyl)-1H-indol-4-yl]oxy)- (PCI) (CA INDEX NAME)


L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 172732-67-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(1-naphthalenyl)ethyl]-1H-indol-4-yl]oxy- (9CI) (CA INDEX NAME)




IN 172732-68-2 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-68-2 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




IN 172732-70-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-71-7 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 172732-69-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((3-chlorophenyl)ethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-69-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((3-chlorophenyl)ethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-70-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


IN 172732-72-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-72-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



IN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




IN 172732-73-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


172732-74-0 CAPLUS
 Butanoic acid, 4-[[3-(aminomonoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (SCI) (CA INDEX NAME)



172732-74-0 CAPLUS
 Butanoic acid, 4-[[3-(aminomonoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (SCI) (CA INDEX NAME)




172733-08-3 CAPLUS
 Acetic acid, [[3-(aminomonoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (SCI) (CA INDEX NAME)



172733-62-5 CAPLUS
 Acetic acid, [[3-(aminomonoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, ammonium salt (SCI) (CA INDEX NAME)

L15 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

L15 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 131326938
 DOCUMENT NUMBER: 131326938
 TITLE: Preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid
 INVENTOR(S): Michael Richard Jeffrey Mucke, John Michael, Jr., Sall, Daniel Zorn Sawyer, Jason Scott
 PATENT ASSIGNOR(S): Lilly and Company, USA
 SOURCE: PCT Int. Appl., 18 pp.
 DOCUMENT TYPE: Patent
 LARGEST: FICXSD
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: English

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9945211	A1	1999-08339	19990420
W1	Ad, Al, Ap, A7, Au, Ad, Ba	239	Bo, Bu, Bv, Ca, Cn, Cx, Cu, Cx, Ce, De, Dk, Df, Dg, Fi, Gb, Gd, Gk, Gm, Gp, Gs, Gt, Gv, Hb, Hc, Hf, Hg, Hh, Hk, Hl, Hm, Hn, Ho, Hp, Hr, Hs, Ht, Hv, Hw, Hx, Hy, Hz, Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Il, Im, In, Io, Ip, Iq, Ir, Is, It, Iu, Iv, Iw, Ix, Iy, Iz, Jb, Jc, Jd, Je, Jf, Jg, Jh, Ji, Jj, Jk, Jl, Jm, Jn, Jo, Jp, Jq, Jr, Js, Jt, Ju, Jv, Jw, Jx, Jy, Jz, Kb, Kc, Kd, Ke, Kf, Kg, Kh, Ki, Kj, Kk, Kl, Km, Kn, Ko, Kp, Kq, Kr, Ks, Kt, Ku, Kv, Kw, Kx, Ky, Kz, La, Lb, Lc, Le, Lf, Lg, Lh, Li, Lj, Lk, Ll, Lm, Ln, Lo, Lp, Lq, Lr, Ls, Lt, Lu, Lv, Lw, Lx, Ly, Lz, Mb, Mc, Md, Me, Mf, Mg, Mh, Mi, Mj, Mk, Ml, Mn, Mo, Mp, Mq, Mr, Ms, Mt, Mu, Mv, Mw, Mx, My, Mz, Nb, Nc, Nd, Ne, Nf, Ng, Nh, Ni, Nj, Nk, Nl, Nm, Nn, No, Np, Nq, Nr, Ns, Nt, Nu, Nv, Nw, Nx, Ny, Nz, Ob, Oc, Od, Oe, Of, Og, Oh, Oi, Oj, Ok, Ol, Om, On, Oo, Op, Oq, Or, Os, Ot, Ou, Ov, Ow, Ox, Oy, Oz, Pb, Pc, Pd, Pe, Pf, Pg, Ph, Pi, Pj, Pk, Pl, Pm, Pn, Po, Pp, Pq, Pr, Ps, Pt, Pu, Pv, Pw, Px, Py, Pz, Qa, Qb, Qc, Qd, Qe, Qf, Qg, Qh, Qi, Qj, Qk, Ql, Qm, Qn, Qo, Qp, Qq, Qr, Qs, Qt, Qu, Qv, Qw, Qx, Qy, Qz, Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh, Ri, Rj, Rk, Rl, Rm, Rn, Ro, Rp, Rq, Rr, Rs, Rt, Ru, Rv, Rw, Rx, Ry, Rz, Sb, Sc, Sd, Se, Sf, Sg, Sh, Si, Sj, Sk, Sl, Sm, Sn, So, Sp, Sq, Sr, Ss, St, Su, Sv, Sw, Sx, Sy, Sz, Ta, Tb, Tc, Td, Te, Tf, Tg, Th, Ti, Tj, Tk, Tl, Tm, Tn, To, Tp, Tq, Tr, Ts, Tu, Tv, Tw, Tx, Ty, Tz, Ub, Uc, Ud, Ue, Uf, Ug, Uh, Ui, Uj, Uk, Ul, Um, Un, Uo, Up, Uq, Ur, Us, Ut, Uv, Uw, Ux, Uy, Uz, Vb, Vc, Vd, Ve, Vf, Vg, Vh, Vi, Vj, Vk, Vl, Vm, Vn, Vo, Vp, Vq, Vr, Vs, Vt, Vu, Vv, Vw, Vx, Vy, Vz, Wb, Wc, Wd, We, Wf, Wg, Wh, Wi, Wj, Wk, Wl, Wm, Wn, Wo, Wp, Wq, Wr, Ws, Wt, Wu, Wv, Ww, Wx, Wy, Wz, Xb, Xc, Xd, Xe, Xf, Xg, Xh, Xi, Xj, Xk, Xl, Xm, Xn, Xo, Xp, Xq, Xr, Xs, Xt, Xu, Xv, Xw, Xx, Xy, Xz, Yb, Yc, Yd, Ye, Yf, Yg, Yh, Yi, Yj, Yk, Yl, Ym, Yn, Yo, Yp, Yq, Yr, Ys, Yt, Yu, Yv, Yw, Yx, Yy, Yz, Zb, Zc, Zd, Ze, Zf, Zg, Zh, Zi, Zj, Zk, Zl, Zm, Zn, Zo, Zp, Zq, Zr, Zs, Zt, Zu, Zv, Zw, Zx, Zy, Zz

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.


ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.


ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.

ABSTRACT: The present invention relates to a method for the preparation of [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid N-morpholino Et ester, which is disclosed, together with its use as a highly bioavailable indole 5-HTA inhibitor compound.


L15 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 249730-08-39
 N1 BAC (Biological activity or effector, except adverse); B5U (Biological study, unspecified); SPM (Synthetic preparation); THU (Therapeutic use); THU (Biological study); THU (Preparation); THU (Use)
 (Group of [[(2-amino-1,2-dimonoethyl)methyl(phenylmethyl)indolyl]oxy]acetic acid N-morpholino Et ester as a 5-HTA inhibitor)
 CN 249730-08-3 CAPLUS
 Acetic acid, [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, 2-(4-morpholino)ethyl ester (SCI) (CA INDEX NAME)




IT 172732-08-3 249730-08-4 249730-10-7
 249730-11-8 249730-12-9 249730-13-0
 249730-14-1 249730-15-2 249730-16-3
 N1 BAC (Biological activity or effector, except adverse); B5U (Biological study, unspecified); THU (Therapeutic use); THU (Biological study); THU (Use)
 (Group of [[(2-amino-1,2-dimonoethyl)methyl(phenylmethyl)indolyl]oxy]acetic acid N-morpholino Et ester as a 5-HTA inhibitor)
 CN 172733-08-3 CAPLUS
 Acetic acid, [[3-(2-amino-1,2-dimonoethyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (SCI) (CA INDEX NAME)




RM 249730-09-4 CAPLUS

Acetic acid, [[3-(aminooxoacetyl)-1-([1,1'-biphenyl]-2-ylmethyl)-2-methyl-1H-indol-4-yl]oxy]-, 2-(diethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)




IN 249730-10-7 CAPUS

CN Acetic acid, [(3-(aminooxyacetyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl]oxy-, ethyl ester (9CI) (CA INDEX NAME)



BN 249730-11-B CAPIJIS

247330-11-8 CAPLUS
CN Acetic acid, [[3-(aminocyclooctyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, 2-[4-(morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



BN 249730-14-1 CAPLUS


249330-14-1 CAPLUS
CN Acetic acid, [[3-(aminooxocapetyl)-2-methyl-1-(1-naphthelenylmethyl)-1H-indol-4-yl]oxy]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




BN 249730-12-9 CAPLUS

249730-12-9 CASUS
CN Acetic acid, [[3-(aminooxyethyl)-2-methyl-1-(phenylmethyl)-1*H*-indol-4-yl]oxy]-, 2-(diethylamino)-2-oxyethyl ester (9CI) [CA INDEX NAME]




RN 249730-13-0 CAPLUS

Acetic acid, [[3-(aminoxocetyl)-2-methyl-1-(1-naphthylethyl)-1H-indol-4-yl]oxy]-, 2-(diethylemino)-2-oxoethyl ester (9CI) (CA INDEX NAME)



JN 249730-16-3 CAPLUS

Acetic acid, [[3-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]-, 2-(diethylamino)-2-oxoethyl ester (9CI) (CA INDEX NAME)



17 122732-60-4

```


AL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
      (prepn. of [(6aminodioxoethyl)methyl(phenylmethyl)indolyl]oxy)acetic

```

acid N-morpholino Et ester

172732-60-4 CAPLUS
Acetic acid, [(3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]- (PCI) (CA INDEX NAME)

115 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 27 OF 3 CAPLIS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999J:30593 CAPLIS
DOCUMENT NUMBER: 131:5185
TITLE: Preparation of 3-aminoethyl-4-indolylisoxycarboxylic acids
and analogs as pPLA2 inhibitors
INVENTOR(S): Watanabe, August Naseru
PATENT ASSIGNEE(S): Eis Lilly and Company, USA
SOURCE: FCT Int. Appl., 56 pp.
CODEN: P130D2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

[illegible]

AS Title compds. {I: R = COCOMH2}[I: R1 = (un)substituted CH2Ph, CH2C6H4Ph-4, CH2C6H4(CH2Ph)-4, etc.; R2 = halo, Na, Et, Pr, cyclopropyl; I of R4, R5 = ZR3 and the other = R or ZR3; R3 = CO2H, SO3H, P(O)(OH)2; R6, R7 = N, halo, alkyl, alkoxy, etc.; when R4 .noteq. N Z = CH2CH2, OCH2, OC(O)Me, etc.; when R5 .noteq. N Z = OZ(C6H4), NHZ(C6H4), C6H4C6H4Z(C6H4), etc.; Z1 = (un)substituted CH2} were pred. as **aPLA2** inhibitors (no data).

L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
Thus, 11 (R1 = CH2Ph, R2 = Et, R4 = OCH2CO2H, R5-R7 = H) was prep.
starting from 2,3-di-(H₂O)-C6H3H3H3O2CHMe3 and K2CO3 (94%) Me


IT starting from 2,3-Ne(ReO)C6H3MnCO2CMe3 and EtCON(OMe)Me.
 172732-60-6P 172732-61-5P 172732-62-6P
 172732-63-7P 172732-64-8P 172732-65-9P
 172732-66-0P 172732-67-1P 172732-68-2P
 172732-69-3P 172732-70-6P 172732-71-7P

172732-72-8P 172732-73-9P 172733-08-3P
172733-42-5P 220862-20-4P
RE: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); SIGL (Signal, signal, signal). PREP (Preparation), INFO (Info).


```

NAME "Acetic acid, [(3-(aminooxalyl-2-methyl-1-(phenylimethyl)-1H-indol-4-yl)oxy]-1-(9CI)" (CA INDEX NAME)
RN 172732-60-4 CAS#
CN Acetic acid, [(3-(aminooxalyl-2-methyl-1-(phenylimethyl)-1H-indol-4-yl)oxy]-1-(9CI) (CA INDEX NAME)

```




HN 172732-61-5 CAPLUS.
 CN Propionic acid, 2-[[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (HCl) (CA INDEX NAME)




RN 172732-62-6 CAPLUS
 CN Acetic acid, [(3-(aminooxyacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-methyl-1H-indol-4-yl)oxy]-(9CI) (CA INDEX NAME)


L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




HN 172732-63-7 CAPLUS
CM Acetic acid, ([3-(4-aminooxocetyl)-1-([1,1'-biphenyl]-3-ylmethyl)-2-methyl-1H-indol-4-yl]oxy)- (9CI) (CA INDEX NAME)



RW 172732-64-8 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-((1,1'-biphenyl)-4-ylmethoxy)-2-methyl-1H-indol-4-yl]oxy]-(9CI) (CA INDEX NAME)




RN 172732-63-9 CAPLUS
 CN Acetic acid, [[3-(aminooxopropyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (SC1) (CA INDEX NAME)



FN 172732-66-D CAPLUS
 CN Acetic acid, [(3-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl)oxy]- (SCI) (CA INDEX NAME)


L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-67-1 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-((1-naphthalenylmethyl)-1H-indol-4-yl)oxy]- (9CI) (CA INDEX NAME)




RN 172732-68-2 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-69-3 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[3-(chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-73-9 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172733-08-3 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 172733-42-5 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, monosodium salt (9CI) (CA INDEX NAME)


L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 172732-70-6 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-71-7 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[1,1'-biphenyl]-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




RN 172732-72-8 CAPLUS
 CN Acetic acid, [[3-(aminooxoacetyl)-1-[[3-(cyclopropyl)-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 220862-20-4 CAPLUS
 CN Butanoic acid, 4-[[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THESE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD


L15 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 172732-65-9 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(2,6-dichlorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-66-0 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-67-1 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)


L15 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 172732-68-2 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-69-3 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylethyl]-2-ethyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-70-6 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylethyl]-2-ethyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)


L15 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




IN 172732-71-7 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylethyl]-2-propyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)



IN 172732-72-8 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylethyl]-2-cyclopropyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-73-9 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-1-[(1,1'-biphenyl)-2-ylethyl]-2-cyclopropyl-1H-indol-4-yl]oxy- (9C1) (CA INDEX NAME)




IN 172732-74-6 CAPLUS
CN Butanoic acid, 4-[(13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy- (9C1) (CA INDEX NAME)


L15 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 172732-06-3 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy-, methyl ester (9C1) (CA INDEX NAME)




IN 172732-42-5 CAPLUS
CN Acetic acid, [13-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy-, monomethyl salt (9C1) (CA INDEX NAME)



● Na


REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L15 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




IN 172732-70-6 CAPLUS

CN Acetic acid, [(3-((aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-ethyl)-1H-indol-4-yl)oxy]- (9CI) (CA INDEX NAME)



IN 172732-71-7 CAPLUS


CN Acetic acid, [(3-((aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-propyl)-1H-indol-4-yl)oxy]- (9CI) (CA INDEX NAME)



IN 172732-72-8 CAPLUS


CN Acetic acid, [(3-((aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- (9CI) (CA INDEX NAME)

L15 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 220660-20-4 CAPLUS


CN Butanoic acid, 4-[(3-((aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD

L15 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




IN 172732-73-9 CAPLUS

CN Acetic acid, [(3-((aminooxoacetyl)-1-((1,1'-biphenyl)-2-ylmethyl)-2-ethyl)-1H-indol-4-yl)oxy]- (9CI) (CA INDEX NAME)



IN 172733-06-3 CAPLUS

CN Acetic acid, [(3-((aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- (9CI) (CA INDEX NAME)



IN 172733-62-5 CAPLUS

CN Acetic acid, [(3-((aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- (9CI) (CA INDEX NAME)

L15 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS

1509146097 CAPLUS

150332289

TITLE: Pharmacology of LY15920/8-1920, [(3-((aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetic acid, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI


INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

INHIBITORS: a new class of anti-inflammatory drugs, SPI

L15 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE BE FORMAT

L15 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:21976 CAPLUS
DOCUMENT NUMBER: 13018:400
TITLE: Processes for preparing 4-substituted-1H-indole-3-
glyoxal
INVENTOR(S): Khas, Vien Van; Martellini, Michael John; Pawlak,
Gregory Matthew
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: Eur. Pat. Appl., 46 pp.
CODEN: EPOKRW
LANGUAGE: Patent
DOCUMENT TYPE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

[illegible]

OTHER SOURCE(S) :
 68




L16 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

[illegible]

17 R1: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 4-substituted-1H-indole-3-glyoxamides with ePLA2

RN 172733-01-3 CAPLUS
 CN Acetic acid, [[3-(aminooxyacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 172732-68-2P 172733-42-8P 218934-51-1P

```

17 172732-30-2P 172733-42-3P 210914-11-1P
AL: SPN (Synthetic preparation); FREE (Preparation)
(presn. of 4-substituted-1H-indole-3-olboxamides with #PLA)


```

```

      (prepn. of 4-substituted-1H-indole-3-glyoxamides with 8FLA2
      -inhibiting activity)
  04  000000-00-00  000000

```


AN 172732-68-2 CAPLUS
 CN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



BM 172733-42-5 CARLDB


ACETIC ACID, [[3-(AMINOOCOACETYL)-2-ETHYL-1-(PHENYL METHYL)-1H-INDOL-4-
 YLMETHYL]-, MONOMEDIUM SALT (9CI) (CA INDEX NAME)

L15 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



● No

RN 218934-51-1 CAPLUS
 CH Acetic acid, [(3-(aminocyclopropyl)-2-ethyl-6-methyl-1-(phenylethyl)-1H-indol-4-yl)oxy]-, monosodium salt (9CI) (CA INDEX NAME)




● **Na**

L15 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:604907 CAPLUS
 DOCUMENT NUMBER: 12918241
 TITLE: Preparation and formulation of indolecarboxylic acid derivatives as ePLA2 inhibitors
 INVENTOR(S): Ohsumi, Mutsuki; Hagiwara, Senji
 SOURCE: Shimizu & Co., Ltd., Japan
 PCT Int. Appl., 39 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: FRENCH
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND DATE	APPLICATION NO. DATE
WO 9837000	19980629	WO 1998-28079 19980219
US 5,811,000	19990629	US 5,811,000 19990629
JP 5,811,000	19990629	JP 5,811,000 19990629
EP 5811000	19990629	EP 5811000 19990629
FR 5,811,000	19990629	FR 5,811,000 19990629
DE 5,811,000	19990629	DE 5,811,000 19990629
GB 5,811,000	19990629	GB 5,811,000 19990629
IT 5,811,000	19990629	IT 5,811,000 19990629
ES 5,811,000	19990629	ES 5,811,000 19990629
PT 5,811,000	19990629	PT 5,811,000 19990629
GR 5,811,000	19990629	GR 5,811,000 19990629
TR 5,811,000	19990629	TR 5,811,000 19990629
RU 5,811,000	19990629	RU 5,811,000 19990629
UA 5,811,000	19990629	UA 5,811,000 19990629
BY 5,811,000	19990629	BY 5,811,000 19990629
MD 5,811,000	19990629	MD 5,811,000 19990629
PL 5,811,000	19990629	PL 5,811,000 19990629
CZ 5,811,000	19990629	CZ 5,811,000 19990629
SK 5,811,000	19990629	SK 5,811,000 19990629
HU 5,811,000	19990629	HU 5,811,000 19990629
RO 5,811,000	19990629	RO 5,811,000 19990629
BE 5,811,000	19990629	BE 5,811,000 19990629
LU 5,811,000	19990629	LU 5,811,000 19990629
IE 5,811,000	19990629	IE 5,811,000 19990629
NO 5,811,000	19990629	NO 5,811,000 19990629
SE 5,811,000	19990629	SE 5,811,000 19990629
DK 5,811,000	19990629	DK 5,811,000 19990629
FI 5,811,000	19990629	FI 5,811,000 19990629
JP 1997-35984	19970229	JP 1997-35984 19970229
WO 1998-27679	19980219	WO 1998-27679 19980219

PRIORITY AFFIL. INFO: JP 1997-35984 19970229
 WO 1998-27679 19980219
 OTHER SOURCE(S): MARPAT 129-18241
 G1




AB The title compounds 1 [R1 = (un)substituted alkyl, etc.; R2 = H, (un)substituted alkyl, etc.; R3 = H, alkyl, etc.] are prepared in an in vitro test for ePLA2 inhibition, the title compd. 1 [R1 = benzyl; R2 = ethyl; R3 = methyl] showed IC50 of 1.7 nM.
 IT 177328-66-3
 RU ePLA2 (biological activity or effector, except adverse); BSU (biological study, unspecified); PEP (preparation); B10L (biological study) (inhibition)
 RU 177328-66-3 CAPLUS
 CN Acetic acid, [(3-(aminooctanoyl)-2-ethyl-1-(phenylethyl)-1H-indol-4-yl)methyl]- (PCL) (CA INDEX NAME)


L15 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



RU 211928-47-2 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)-, diisodium salt (PCL) (CA INDEX NAME)




● 2 Hs
 IT 211928-35-2P 211928-64-2P 211928-60-2P
 211928-91-2P 211928-60-2P
 RU RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); NACT (Neutralization or reaction)
 (preparation of indolecarboxylic acid derivs. as ePLA2 inhibitors)
 RU 211928-56-2 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-2-ethyl-4-(2-methoxy-2-oxoethyl)-1-(phenylethyl)-, methyl ester (PCL) (CA INDEX NAME)




RU 211928-56-3 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-2-ethyl-4-[2-(1-methylethoxy)-2-oxoethyl]-1-(phenylethyl)-, 1-methylethyl ester (PCL) (CA INDEX NAME)


L15 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 211928-44-2P 211928-45-2P 211928-46-1P
 211928-47-2P
 RU RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); NACT (Neutralization or reaction)
 (preparation of indolecarboxylic acid derivs. as ePLA2 inhibitors)
 RU 211928-44-2 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)-, 6-methyl ester (PCL) (CA INDEX NAME)




RU 211928-48-0 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)- (PCL) (CA INDEX NAME)




RU 211928-46-1 CAPLUS
 CN 1H-indole-6-carboxylic acid, 3-(aminooctanoyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)-, 6-(1-methylethyl) ester (PCL) (CA INDEX NAME)


L15 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RU 211928-60-9 CAPLUS
 CN 1H-indole-3-acetamide, 6-[(acetyl(methyl)-2-ethyl-1-phenylethyl)-1-(phenylethyl)-1-(phenylethyl)]- (PCL) (CA INDEX NAME)






RU 211928-61-0 CAPLUS
 CN 1H-indole-3-acetamide, 6-[(acetyl(methyl)-2-ethyl-4-hydroxy-1-phenylethyl)-1-(phenylethyl)-1-(phenylethyl)]- (PCL) (CA INDEX NAME)







RU 211928-62-1 CAPLUS
 CN Acetic acid, [(6-[(acetyl(methyl)-2-ethyl-1-(phenylethyl)-1-(phenylethyl)-1-(phenylethyl)]-1H-indol-4-yl)oxy]-, methyl ester (PCL) (CA INDEX NAME)






L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-66-0 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(4-fluorophenyl)methyl]-2-methyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-67-1 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(1-naphthalenyl)methyl]-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-68-2 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)



L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 172732-72-8 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-73-9 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(1,1'-biphenyl)-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-74-0 CAPLUS
CN Butanoic acid, 4-[[3-[[aminooxoacetyl]-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-75-1 CAPLUS
CN Butanoic acid, 4-[[3-[[aminooxoacetyl]-1-(phenylmethyl)-1H-indol-5-yl]oxy]- (9CI) (CA INDEX NAME)


L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 172732-69-3 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(3-chlorophenyl)methyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-70-6 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(1,1'-biphenyl)-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)RN 172732-71-7 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-1-[(1,1'-biphenyl)-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]- (9CI) (CA INDEX NAME)

L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 172733-42-5 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, monosodium salt (9CI) (CA INDEX NAME)

● Na


IT 172732-80-8P 172732-82-8P 172732-88-4P
172732-87-8P 172732-81-1P 172732-84-4P
172732-86-8P 172732-81-6P 172732-88-8P
172732-88-2P 172732-11-8P 172732-15-2P
172732-80-8P 172732-28-4P 172732-28-8P
172732-31-2P 172732-32-2P 172732-32-4P
172732-32-6PXis: RCT (Reactant); SW (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(groups of indole-3-glyoxylamides as #PLA3 inhibitors)RN 172732-60-8 CAPLUS
CN Acetic acid, [3-[[aminooxoacetyl]-2-methyl-1-(phenylmethyl)-1H-indol-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 172732-62-0 CAPLUS
CN Propanoic acid, 2-[[[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)



RN 172732-66-4 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)



RN 172732-67-5 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]-, monosodium salt (9C1) (CA INDEX NAME)




● Na


RN 172732-91-1 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-3-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)

L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN Acetic acid, [[3-(aminooxoacetyl)-2-methyl-1-(3-naphthalenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)



RN 172733-04-3 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-11-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[3-chlorophenyl]methyl]-2-ethyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-18-2 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-ethyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)


L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172733-84-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-4-ylmethyl]-2-methyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)



RN 172733-88-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[2,6-dichlorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-01-6 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[4-fluorophenyl]methyl]-2-methyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-05-0 CAPLUS


L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 172733-20-9 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-propyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-25-4 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-cyclopropyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-28-8 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-1-[[[1,1'-biphenyl]-2-ylmethyl]-2-cyclopropyl-1H-indol-4-yl]oxy]-, methyl ester (9C1) (CA INDEX NAME)




RN 172733-31-2 CAPLUS
CN 1H-indole-3-acetamide, 2-ethyl-5-methoxy-.alpha.-exo-1-(phenylmethyl)-

L15 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2003 ACS (Continued)
(PCI) (CA INDEX NAME)

RN 172733-32-3 CAPLUS
CN 1H-Indole-3-acetamide, 2-ethyl-5-hydroxy-, elphe.-oxo-1-(phenylmethyl)-
(SCI) (CA INDEX NAME)



FN 172733-33-4 CASUS
 CN Butanoic acid, 4-[(3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-5-yl)oxy]-, 1,1-dimethylethyl ester (SCI) (CA INDEX NAME)




HN 172733-35-6 CAPLUS
 CN Butanoic acid, 4-[[3-(methoxycarbonyl)-1-(phenylethyl)-1H-indol-5-yl]oxy]-
 , ethyl ester (9CI) (CA INDEX NAME)

L15 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:621499 CAPLUS
DOCUMENT NUMBER: 123 123964
TITLE: Preparation of 18-iodole-3-acetamides as α 7L2
inhibitors.
INVENTOR(S): Sack, Nicholas James; Dillard, Robert Delane; Drahman,
Susan Elizabeth; Hermann, Robert Ball; Schevitz,
Richard Walter
PATENT ASSIGNEE(S): Lilly, Eli, and Co., USA
SOURCE: Eur. Pat. Appl., 123 pp.
CODING: EPXXXX
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

[illegible]

115 ANSWER 36 OF 37 CAPLAS COPYRIGHT 2003 ACS (Continued)

[illegible]

RN 164082-87-5 CAPLUS
CN 1H-Indole-3-acetamide, 1-[(3-chlorophenyl)methyl]-2-ethyl-4-methoxy-,
.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 164082-89-7 CAPLUS
 CN 3H-Indole-3-acetamide, 4-methoxy-, alpha.-oxo-1-(phenylmethyl)- 'SCI' (CA
 INDEX NAME)



=> fil reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
172.94	550.57

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-24.09	-25.39

FILE 'REGISTRY' ENTERED AT 16:47:09 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9
DICTIONARY FILE UPDATES: 22 MAY 2003 HIGHEST RN 519137-84-9

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10069824.str

L16 STRUCTURE UPLOADED

=> d

L16 HAS NO ANSWERS

L16 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 16:40:09 ON 23 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:41:16 ON 23 MAY 2003

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 2 S L1 FULL

FILE 'CAPLUS' ENTERED AT 16:41:56 ON 23 MAY 2003

L4 2 S L3

FILE 'REGISTRY' ENTERED AT 16:42:20 ON 23 MAY 2003

L5 STRUCTURE UPLOADED
L6 50 S L5
L7 1927 S L5 FULL
L8 STRUCTURE UPLOADED
L9 570 S L8 FULL SUB=L7

FILE 'CAPLUS' ENTERED AT 16:44:16 ON 23 MAY 2003

L10 221 S L9

FILE 'REGISTRY' ENTERED AT 16:44:42 ON 23 MAY 2003

L11 STRUCTURE UPLOADED
L12 484 S L11 FULL SUB=L9

FILE 'CAPLUS' ENTERED AT 16:45:03 ON 23 MAY 2003

L13 193 S L12
L14 5 S L13 AND SPLA
L15 37 S L13 AND SPLA2

FILE 'REGISTRY' ENTERED AT 16:47:09 ON 23 MAY 2003

L16 STRUCTURE UPLOADED

=> s l16 subset=l7 full
FULL SUBSET SEARCH INITIATED 16:47:57 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1927 TO ITERATE

100.0% PROCESSED 1927 ITERATIONS 60 ANSWERS
SEARCH TIME: 00.00.01

L17 60 SEA SUB=L7 SSS FUL L16

=> fil caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	35.70	586.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-25.39

FILE 'CAPLUS' ENTERED AT 16:48:03 ON 23 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 May 2003 VOL 138 ISS 22
FILE LAST UPDATED: 22 May 2003 (20030522/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l17
L18 17 L17
=> d ibib abs hitstr 1-17

L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 348112-47-0 CAPLUS
CN 2-Propenoic acid, 3-[[1-[(4-chlorophenyl)methyl]-3-[(2,5-dihydro-5-oxo-3-furanyl)ethynyl]indol-4-yl]-1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 348112-48-1 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-alpha-oxo-4-[(2-propenyl)oxy]methyl]- (9CI) (CA INDEX NAME)


L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348111-63-1 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-5-cyano-N-(2,5-dihydro-5-oxo-3-furanyl)-alpha-oxo- (9CI) (CA INDEX NAME)




RN 348111-67-5 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 348111-88-6 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-6-methyl- (9CI) (CA INDEX NAME)

L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348112-53-8 CAPLUS
CN 18-Indole-4-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[(2,5-dihydro-5-oxo-3-furanyl)ethynyl]indol-4-yl]- (9CI) (CA INDEX NAME)




IT 348111-62-0P 348111-63-1P 348111-67-5P
348111-88-6P 348111-90-0P 348112-48-0P
348112-53-8P 348112-54-0P
348112-55-0P 348112-56-1P 348112-57-2P
348112-58-4P


RL BAC (Biological activity or effector, except adverse); MSU (Biological study, unclassified); SYN (Synthetic preparation); TSD (Therapeutic use); RIG (Biological study); PREP (Preparation); USES (Uses) (from: of 2-[18-indol-3-yl]-2-methoxyacetamide antitumor agents by reaction of indoles with methyl chloride followed by oxidation with methylchlorophenones or monofurones)

RN 348111-42-0 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-4-methyl- (9CI) (CA INDEX NAME)


L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 348111-90-0 CAPLUS
CN 18-Indole-3-acetamide, 1-[(4-chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-7-methyl- (9CI) (CA INDEX NAME)




RN 348112-05-0 CAPLUS
CN 18-Indole-4-carboxylic acid, 1-[(4-chlorophenyl)methyl]-3-[(2,5-dihydro-5-oxo-3-furanyl)ethynyl]indol-4-yl]- (9CI) (CA INDEX NAME)



L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


NN 348112-31-2 CAPLUS

CN 1H-Indole-4-carboxylic acid, 1-[[4-(chlorophenyl)methyl]-3-[[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-1H-indol-4-yl]-, (2H) (PCI) (CA INDEX NAME)



NN 348112-66-9 CAPLUS

CN 1H-Indole-3-acetamide, 1-[[4-(chlorophenyl)methyl]-4-cyano-N-(2,5-dihydro-5-oxo-3-furanyl)-alpha-oxo- (PCI) (CA INDEX NAME)




NN 348112-84-9 CAPLUS

CN 2-Furancarboxic acid, 3-[[1-[[4-(chlorophenyl)methyl]-3-[[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-1H-indol-4-yl]-, (2H) (PCI) (CA INDEX NAME)


Double bond geometry as shown.

L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



NN 348112-57-2 CAPLUS


CN 1H-Indole-3-acetamide, 4-[[[(2-aminoethyl)amino]carbonyl]-1-[[4-(chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-alpha-oxo- (PCI) (CA INDEX NAME)



NN 348112-59-4 CAPLUS


CN 1H-Indole-3-acetamide, 1-[[4-(chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-4-(hydroxymethyl)-alpha-oxo- (PCI) (CA INDEX NAME)

L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



NN 348112-55-8 CAPLUS


CN 1H-Indole-3-acetamide, 1-[[4-(chlorophenyl)methyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-4-[[[(2-dimethylamino)ethyl]amino]carbonyl]-alpha-oxo- (PCI) (CA INDEX NAME)



NN 348112-56-1 CAPLUS

CN 1H-Indole-3-acetamide, 1-[[4-(chlorophenyl)methyl]-4-[[[(diethylamino)oxy]carbonyl]-N-(2,5-dihydro-5-oxo-3-furanyl)-alpha-oxo- (PCI) (CA INDEX NAME)

L18 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 248112-58-3

AL ACT (Reactant) RACT (Reactant or reagent)
(reactant prep. of 2-[[1H-indol-3-yl]-2-oxoacetamide antitumor agents by reaction of indoles with acetyl chloride followed by acylation with acetoxyphenylamines or aminofuranes)

NN 348112-58-3 CAPLUS

CN Carbamic acid, [2-[[1-[[4-(chlorophenyl)methyl]-3-[[[(2,5-dihydro-5-oxo-3-furanyl)amino]oxoacetyl]-1H-indol-4-yl]]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (PCI) (CA INDEX NAME)



REFERENCE COUNT: 2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE XF FORMAT

L18 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 200107212 CAPLUS

DOCUMENT NUMBER: 131/0417

TITLE:

A molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2

AUTHOR(S): Bernack, Philippe; Pantore, Marco; Serthon, Jean-Yves; Chretien, Jacques R.

CORPORATE SOURCE: Laboratory of Chemometrics and Bioinformatics, University of Orleans, Orleans, 41067, Fr

SOURCE: European Journal of Medicinal Chemistry 2001, 36(1), 1-19

COORD: KEMCAL; ISSN: 0223-5234

PUBLISHER: Editions Scientifiques et Medicales Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Automated docking using protein-based alignment was performed for a series of 189 indole inhibitors of the human non-pneumatic secretory phospholipase A2 (hnp-PLA2). All the substituted indoles were docked to the crystal structure of hnp-PLA2 and a three-dimensional QSAR model was then established using the CoMPA method. The set of 189 compounds was divided into two subsets, the first one constituting the training set (126 compounds), while the second constituted the test set (63 compounds). The established CoMPA model derived from the training set was then applied to the test set. A good correlation between predicted and experimental activity data allows to validate the 3D QSAR model. A second and global 3D QSAR including all the compounds was established, allowing the creation of the hnp-PLA2 pharmacophore.

18299-07-6 18299-07-6 18299-08-8

IT RI RAC (Biological activity or effector, except adverse); RSU (Biological study, unspecified); FIV (Properties); RIG (Biological study)

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-07-6 18299-07-6 18299-08-8

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-1-(phenylmethyl)-5-penyl-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

L18 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

ACCESSION NUMBER: 200107212 CAPLUS

DOCUMENT NUMBER: 131/0417

TITLE:

A molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2

AUTHOR(S): Bernack, Philippe; Pantore, Marco; Serthon, Jean-Yves; Chretien, Jacques R.

CORPORATE SOURCE: Laboratory of Chemometrics and Bioinformatics, University of Orleans, Orleans, 41067, Fr

SOURCE: European Journal of Medicinal Chemistry 2001, 36(1), 1-19

COORD: KEMCAL; ISSN: 0223-5234

PUBLISHER: Editions Scientifiques et Medicales Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Automated docking using protein-based alignment was performed for a series of 189 indole inhibitors of the human non-pneumatic secretory phospholipase A2 (hnp-PLA2). All the substituted indoles were docked to the crystal structure of hnp-PLA2 and a three-dimensional QSAR model was then established using the CoMPA method. The set of 189 compounds was divided into two subsets, the first one constituting the training set (126 compounds), while the second constituted the test set (63 compounds). The established CoMPA model derived from the training set was then applied to the test set. A good correlation between predicted and experimental activity data allows to validate the 3D QSAR model. A second and global 3D QSAR including all the compounds was established, allowing the creation of the hnp-PLA2 pharmacophore.

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS

CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)

18299-08-5 CAPLUS


CA (molecular modelling and 3D QSAR study of a large series of indole inhibitors of human non-pneumatic secretory phospholipase A2)

EN Acetic acid, [[3-(aminooxycetyl)-2-ethyl-6-methyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]- (NC1) (CA INDEX NAME)


18299-08-5 CAPLUS

AS Title compds. [1: R2 = H or (un)substituted alkyl; R3 = H or 1 or 2 of halo, alkyl, alkoxy, etc.; R4 = C(X)(X)(X)NR1; R = H, (un)substituted alkyl, CO2CH2Ph, etc.; R1 = (un)substituted Ph, -pyridyl, -pyrimidyl, etc.; R11 = (CH2CH2)2NR3; R7 = alkyl, Ph, CHPh2, etc.; K = O or S] were

L18 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)
 premed. Then, indole was N-alkylated by 4-FC6H4CH2Cl and the product
 isolated by (DCI)2 to give, after 4-methylpyridine oxidation, 1 (R2 =
 CH2CH2CH2-4, R3 = H, R4 = COCONH2, R1 = 4-pyridyl). Data for biol.
 activity of 1 were:
 IT 204024-03-1P 245661-2P-5P 245661-3P-6P
 R2: BAC (biological activity or effector, except adverse); BSU (biological
 study, unaltered/used); SPN (synthetic preparation); THU (therapeutic use);
 BSH (biological study); PBP (preparation); USS (uses)
 (prepn. of indolylglynylamides as antitumor agents)
 RN 204024-03-1 CAPLUS
 CN Carbanic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-
 pyridyl)amino]acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (SCI) (CA
 INDEX NAME)




RN 245661-3P-5 CAPLUS
 CN Carbanic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-
 pyridyl)amino]acetyl]-1H-indol-5-yl]methyl]-, methyl ester (SCI) (CA
 INDEX NAME)



RN 245661-3P-6 CAPLUS
 CN Carbanic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-
 pyridyl)amino]acetyl]-1H-indol-5-yl]methyl]-, 2-methylpropyl ester (SCI)
 (CA INDEX NAME)

L18 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 130133017
 DOCUMENT NUMBER: 130133017
 TITLE: Method for the treatment of disorders associated with
 apoptosis using N-heterocyclic glynylamide compounds
 INVENTOR(S): Yoshino, Tetsuro; Takano, Kenji
 PATENT ASSIGNOR(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 104 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924033	A1	19990520	WO 1997-2F4104	19971112
CA 2308269	AA	19990520	CA 1998-2308269	19981110
WO 9924026	A2	19990520	WO 1998-2F5042	19981110
WO 9924026	A3	19990711		
AU 9397630	A1	19990730	EP 1998-931749	19981110
EP 1071630	A2	20000927	EP 1998-931749	19981110
FI 971630	A2	20000927	EP 1998-931749	19981110
JP 1071630	A2	20000927	EP 1998-931749	19981110
RU 971630	A2	20000927	EP 1998-931749	19981110
US 971630	A2	20000927	EP 1998-931749	19981110
WO 9924026	A2	19990520	WO 1998-2F5042	19981110
WO 9924026	A3	19990711		


FAVORABLE ABST. INFO. 1
 OTHER SOURCE(S): MORPAT 130133017
 GI




AB A method is disclosed for the treatment of disorders associated with
 apoptosis using N-heterocyclic glynylamide compounds. 1 (R2 = CH2CH2CH2-4,
 R3 = H, R4 = COCONH2, R1 = 4-pyridyl). Data for biol. activity of 1 were:
 IT 204024-03-1P 245661-2P-5P 245661-3P-6P
 R2: BAC (biological activity or effector, except adverse); BSU (biological
 study, unaltered/used); SPN (synthetic preparation); THU (therapeutic use);
 BSH (biological study); PBP (preparation); USS (uses)
 (prepn. of indolylglynylamides as antitumor agents)
 RN 204024-03-1 CAPLUS
 CN Carbanic acid, [[1-[(4-fluorophenyl)methyl]-3-[[oxo(4-
 pyridyl)amino]acetyl]-1H-indol-5-yl]methyl]-, ethyl ester (SCI) (CA
 INDEX NAME)

L18 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)


IT 218925-46-6P 218925-46-6P 218925-46-6P
 245661-0P-3P 245661-10-6P 245661-11-7P
 R2: BAC (biological activity or effector, except adverse); BSU (biological
 study, unaltered/used); SPN (synthetic preparation); THU (therapeutic use);
 BSH (biological study); PBP (preparation); USS (uses)
 (method for treatment of disorders associated with apoptosis using
 N-heterocyclic glynylamide compounds)
 RN 211925-44-9 CAPLUS
 CN 18-Indole-6-carboxylic acid, 3-[[methyl(ethyl)ester]-2-ethyl-
 1-(phenylmethyl)-, 6-methyl ester (SCI) (CA INDEX NAME)



RN 211925-45-0 CAPLUS
 CN 18-Indole-6-carboxylic acid, 3-[[methyl(ethyl)ester]-2-ethyl-
 1-(phenylmethyl)-, 6-methyl ester (SCI) (CA INDEX NAME)




RN 211925-46-1 CAPLUS
 CN 18-Indole-6-carboxylic acid, 3-[[methyl(ethyl)ester]-2-ethyl-
 1-(phenylmethyl)-, 6-methyl ester (SCI) (CA INDEX NAME)




RN 224561-09-3 CAPLUS
 CN 18-Indole-6-carboxylic acid, 3-[[methyl(ethyl)ester]-2-ethyl-
 1-(phenylmethyl)-, 6-methyl ester (SCI) (CA INDEX NAME)

study, unclassified); SPN (Synthetic preparation); TMU (Therapeutic use);
BIOI (Biological study); PREP (Preparation); USES (Uses)
(prepn. of indole-3-carboxylic acid deriva. as aFIA2 inhibitors)
RUI 211925-44-9 CAPLUS
CN 1H-Indola-6-carboxylic acid, 3-(aminomethyl)-4-(methoxymethyl)-2-ethyl-


L18 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 211925-45-0 CAPLUS
CN 18-indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)- (SCI) (CA INDEX NAME)




IN 211925-46-1 CAPLUS
CN 18-indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)-, 6-[(ethylethyl) ester (SCI) (CA INDEX NAME)




IN 211925-47-2 CAPLUS
CN 18-indole-6-carboxylic acid, 3-(aminooxoacetyl)-4-(carboxymethyl)-2-ethyl-1-(phenylethyl)-, diacid salt (SCI) (CA INDEX NAME)


L18 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IN 211925-61-0 CAPLUS
CN 18-indole-3-acetamide, 6-[(acetyloxy)methyl]-2-ethyl-4-hydroxy-.alpha.-oxo-1-(phenylethyl)- (SCI) (CA INDEX NAME)




IN 211925-62-1 CAPLUS
CN Acetic acid, [[6-[(acetyloxy)methyl]-3-(aminooxoacetyl)-2-ethyl-1-(phenylethyl)-18-indol-4-yl]oxy]-, methyl ester (SCI) (CA INDEX NAME)




IT 211925-63-2 CAPLUS
AL: SPN (Synthetic preparation); PREP (Preparation)
[Synth. of indolecarboxylic acid deriva. as sPLA2 inhibitors]
IN 211925-63-2 CAPLUS
CN Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-6-(hydroxymethyl)-1-(phenylethyl)-18-indol-4-yl]oxy]- (SCI) (CA INDEX NAME)

L18 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




●2 Na

IT 211925-64-2 CAPLUS
AL: PCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent)
[Synth. of indolecarboxylic acid deriva. as sPLA2 inhibitors]
IN 211925-64-2 CAPLUS
CN 18-indole-6-carboxylic acid, 3-(aminooxoacetyl)-2-ethyl-4-(2-methoxy-2-oxoethyl)-1-(phenylethyl)-, methyl ester (SCI) (CA INDEX NAME)




IN 211925-65-3 CAPLUS
CN 18-indole-6-carboxylic acid, 3-(aminooxoacetyl)-2-ethyl-4-[(2-(1-methylethoxy)-2-oxoethyl)-1-(phenylethyl)-, 1-methylethyl ester (SCI) (CA INDEX NAME)



IN 211925-66-9 CAPLUS
CN 18-Indole-3-acetamide, 6-[(acetyloxy)methyl]-2-ethyl-.alpha.-oxo-4-

L18 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1998:175908 CAPLUS
 DOCUMENT NUMBER: 12175908

TITLE: Preparation of new, N-substituted indole-3-glyoxalimides as antitubercular, antileishmanic agents and immunosuppressants/immunosensitizers
 AUTHORS(S): Grollmann, Heidemarie; Grollmann, Rüdiger; Reckardt, Digi; Peters, Siegfried; Steffan, Rainer; Kay, Gerd; Grollmann, Heidemarie; Grollmann, Rüdiger
 PATENT ASSIGNER(S): RCT Int. Ag., 40 pp.
 SOURCE: COINQ 731032
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: Patent

PATENT NO. KIND DATE APPLICATION NO. DATE
 WO 9809946 A1 1998-03-12 WO 1997-046474 19970816
 V: AU, BR, CN, DE, ES, FR, GB, JP, KR, IL, IT, LU, MX, NL, NZ, PL, RU, SE, SG, SI, US
 RPI: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 ZE 1946416 A1 1998-03-12 US 1996-104010 19960804
 AU 5740138 A1 1999-02-26 AU 1997-40158 19970816
 AU 735251 A1 1999-02-26 AU 1997-40158 19970816
 AU 810663 A1 1999-02-26 EP 1997-937586 19970816
 R: AT, BE, BR, CN, DE, ES, FR, GB, GR, IE, IL, LU, NL, NZ, SE, SG, SI, US
 ZE 1278478 A1 1999-02-26 CN 1997-017119 19970816
 SE 9712808 A 1999-11-23 SN 1997-12808 19970816
 JP 200055099 A2 2000-04-25 JP 1999-12167 19970816
 JP 3296437 A2 2000-07-02
 ME 336476 A 2000-03-26 ME 1997-334496 19970816
 ZA 9707475 A 1998-02-19 ZA 1997-7475 19970820
 CA 2215013 A 1998-03-12 CA 1997-2215013 19970904
 CA 2218013 C 2002-03-05
 US 6026223 A 1999-02-23 US 1997-023206 19970808
 US 9610701 A 1998-03-04 WO 1999-1071 19990804
 US 534460 A1 2002-02-05 US 1999-499263 19990910
 US 200201026 A1 2002-04-26 US 2002-04936 20020130
 US 200300081 A1 1999-03-04 US 2003-081 20030130
 DE 1999-1848350 A 1999-08-06
 US 1997-247474 V 19970816
 US 1997-253206 A3 19970808
 US 1999-499263 A3 19990930

PRIORITY AT/AN, INFO.

OTHER SOURCE(S): HANPAT 120-221785
 GI




L18 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 12646974
 DOCUMENT NUMBER: 12646974

TITLE: Indole-3-glyoxalimide derivatives as inhibitors of human nonpancreatic secretory phospholipase A2
 AUTHORS(S): Trachten, Susan E.; Bach, Nicholas A.; O'Neil, Robert D.; Berry, Dennis R.; Carlson, Donald S.; Chergadia, Nicholas J.; Clavon, David K.; Hartley, Lawrence W.; Johnson, Lea M., et al.
 CORPORATE SOURCE: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46205, USA
 SOURCE: Journal of Medicinal Chemistry (1996), 39(26), 5159-5175
 COINQ: JCNWAS; ISSN: 0021-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The preceding papers of this series detail the development of functionalized indole-3-glyoxalimides as inhibitors of hspg-PLA2. We describe here the extension of the structure-activity relationship to include a series of indole-3-glyoxalimide derivatives. Functionalized indole-3-glyoxalimides with an acidic substituent appended to the 4- or 5-position of the indole ring were prepared and tested as inhibitors of hspg-PLA2. It was found that the indole-3-glyoxalimides with a 4-oxoacetic acid substituent had optimal inhibitory activity. These inhibitors exhibited an improvement in potency over the best of the indole-3-glyoxalimides, and 17315920 (6a) was selected for evaluation clin. as an hspg-PLA2 inhibitor.

IT 185298-07-39 185298-72-09 185298-07-49
 185298-08-49
 RI RAC (Biological activity or effector, except adverse); RSU (Biological study, unclassified); SPN (Synthetic preparation); TMS (Therapeutic use); TMS (Therapeutic use); PREP (Preparation) USES (Use)
 (Prep. of N-substituted indole-3-glyoxalimides as antitubercular, antileishmanic agents and immunosuppressants/immunosensitizers)

CN 185298-07-39 CAPLUS
 ACetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-5-(2-propenyl)-1H-indol-4-yl]oxy]- (PCI) (CA INDEX NAME)




CN 185298-72-09 CAPLUS
 ACetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-5-propenyl-1H-indol-4-yl]oxy]- (PCI) (CA INDEX NAME)

L18 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

AB The title compds. [I: R = H, (unsubstituted C1-6 alkyl); R1 = (unsubstituted Ph, pyridyl, pyrimidinyl, etc.); R2 = atom to close (N-substituted) piperazine ring; R3 = H, (unsubstituted C1-6 alkyl); (unsubstituted benzoyl); R4 = H, OH, C1-6 alkyl, C1-7 cycloalkyl, halo, NO2, amino, heteroaryl, etc.; I = O, S] and their acid salts were prep., e.g., by N-alkylation of indole with N2-bearing reactants followed by acylation with a dicarbonyl halide and amidation of the remaining acid halide function. For example, a title compd. I (R = R3 = R4 = H, R1 = 4-pyridyl; R2 = 4-FCOCH2Cl, I = O) (prep. by benzylation of indole with 4-FCOCH2Cl), acylation of the intermediate with (COCl)2 and amidation of the acyl chloride with 4-aminopyridine given) at 10 mg/kg i.p. in guinea pigs gave 15-4% inhibition of allergen-induced late-phase eosinophilia, vs. 47.0% for cyclosporin A.


IT 200208-02-19
 RI RAC (Biological activity or effector, except adverse); RSU (Biological study, unclassified); SPN (Synthetic preparation); TMS (Therapeutic use); TMS (Therapeutic use); PREP (Preparation) USES (Use)
 (Prep. of N-substituted indole-3-glyoxalimides as antitubercular, antileishmanic agents and immunosuppressants/immunosensitizers)
 CN 200208-02-19 CAPLUS
 Carbamic acid, [[1-[(4-fluorophenyl)methyl]-3-oxo-4-pyridyl]amino]acetyl-1H-indol-5-yl]methyl]-, ethyl ester (PCI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD

L18 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)

HO2C-CH2-CH2-C(=O)-NH2
 n-Pr
 CH2-Ph
 CN 185298-07-4 CAPLUS
 2-Propenoic acid, 3-[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]- (PCI) (CA INDEX NAME)




CN 185298-08-5 CAPLUS
 1H-indol-4-propenoic acid, 3-[3-(aminooxoacetyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]- (PCI) (CA INDEX NAME)




IT 185298-18-4
 RI RCT (Reactant); RACT (Reactant or reagent)
 (Prep. and use of indole-3-glyoxalimides as inhibitors of human nonpancreatic secretory phospholipase A2)
 CN 185298-18-4 CAPLUS
 Acetic acid, [[3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-5-(2-propenyl)-1H-indol-4-yl]oxy]-, ethyl ester (PCI) (CA INDEX NAME)


118 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



IT 185298-59-39 185298-05-29 185298-06-39
 RI ACZ (Reactant): SYN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Ingen. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory phospholipase A2)
 RN 185298-59-3 CAPLUS
 CN Acetic acid, [[3-(aminooctyl)-2-ethyl-1-(phenylmethyl)-5-propyl-1H-indol-4-yl]methyl-, ethyl ester (SCI) (CA INDEX NAME)




RN 185299-05-2 CAPLUS
 CN 2-Propenoic acid, 3-[[3-(aminooctyl)-2-methyl-1-(phenylmethyl)-1H-indol-4-yl]-, methyl ester (SCI) (CA INDEX NAME)



RN 185299-06-3 CAPLUS
 CN 1H-Indole-4-propenoic acid, 3-(aminooctyl)-2-methyl-1-(phenylmethyl)-, methyl ester (SCI) (CA INDEX NAME)


118 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 126184068
 TITLE: Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 2. Indole-3-acetamides with Additional Functionality
 AUTHOR(S): Ollard, Robert D.; Bach, Nicholas J.; Brabson, Susan F.; Berry, Dennis B.; Carlson, Ronald D.; Chirgates, Nicholas V.; Clewton, David K.; Hartley, Lawrence W.; Johnson, Lisa M. et al.
 CORPORATE SOURCE: Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46225, USA
 SOURCE: Journal of Medicinal Chemistry (1996), 39(26), 1177-1184
 CODEN: JMCMAH ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: English
 LANGUAGE: English
 AB As reported in our previous paper, a series of indole-3-acetamides which possessed potency and selectivity as inhibitors of human nonpancreatic secretory phospholipase A2 (hnpA2) was developed. The design of these compounds was based on information derived from x-ray crystal structures detd. for complexes between the enzyme and its inhibitors. We describe here the further implementation of this structure-based design strategy and continued SAR development to produce indole-3-acetamides with additional functionalities which increased interaction with important residues within the enzyme active site. These efforts led to inhibitors with substantially enhanced potency and selectivity.
 IT 185301-68-49 185301-68-29 185301-73-99
 RI ACZ (Reactant): SYN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Ingen. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory phospholipase A2)
 RN 185301-68-4 CAPLUS
 CN 1H-Indole-3-butyric acid, 3-(aminooctyl)-2-methyl-7-methyl-7-methyl-1-(phenylmethyl)-, ethyl ester (SCI) (CA INDEX NAME)




RN 185301-68-3 CAPLUS
 CN Butanoic acid, 4-[[[3-(aminooctyl)-2,7-dimethyl-1-(phenylmethyl)-1H-indol-5-yl]methyl-, ethyl ester (SCI) (CA INDEX NAME)

118 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 185301-73-9 185301-73-99 185301-73-99
 RI ACZ (Reactant): SYN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Ingen. and SAR of indoleacetamides as inhibitors of human nonpancreatic secretory phospholipase A2)
 RN 185301-73-9 CAPLUS
 CN Butanoic acid, 4-[[[3-(aminooctyl)-2,7-dimethyl-1-(phenylmethyl)-1H-indol-5-yl]methyl-, ethyl ester (SCI) (CA INDEX NAME)

118 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 185301-73-9 CAPLUS
 CN Butanoic acid, 4-[[[3-(aminooctyl)-2,7-dimethyl-1-(phenylmethyl)-1H-indol-5-yl]methyl-, ethyl ester (SCI) (CA INDEX NAME)

FM 123885-1D-9 CAPLUS
CM Indole-6-carboxylic acid, 2-ethyl-1-phenethyl-3-propyloxaroyl- (6CI) (CA
INDEX NAME)



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

77.53

663.80

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.07

-36.46

STN INTERNATIONAL LOGOFF AT 16:48:49 ON 23 MAY 2003